Sanofi and Sobi's hemophilia drug meets phase III primary endpoint
A phase III study conducted by pharmaceutical firms Sanofi and Sobi investigating potential hemophilia A treatment efanesoctocog has met its primary endpoint.
by marketwire, translated by daniel pedersen
Sanofi and Swedish Orphan Biovitrum, commonly known as Sobi, have presented positive top line results from a phase III trial with efanesoctocog, a hemophilia A treatment candidate, as reported in a press release on Wednesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
